Navigation Links
Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/5/2008

REHOVOT, Israel and JERSEY CITY, New Jersey, November 5 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics, announced today it will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Wednesday, November 10 at The New York Palace Hotel in New York City.

About MicroRNA

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on c
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2007 Healthcare Conference
2. Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008
3. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
4. UC San Diego to lead nationwide program in pharmacogenomics
5. NeoGenomics to Present at the Noble Financial Equity Conference
6. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
7. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
8. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
9. AutoGenomics Receives a Key European Patent for HPV Detection
10. Genomics of Cardiovascular Disease: Current Clinical Applications
11. Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., , FORT LAUDERDALE, Fla., Dec. 1 /PRNews... of patient enrollment in the randomized clinical ...g Stent (Combo Stent). ,, A prospective, random... E valuation of an ablu M inal sirolimus coat ... patients at up to 20 sites in Asia, Australia, Eu...
(Date:12/1/2009)... (December 1, 2009) The ADEAGies Foundation will ...hievement Award at the Gies Awards celebration to ...n conjunction with the 2010 ADEA Annual Session & ... Innovation, and Achievement recognize contributio...tion initiatives. For a complete listing of Gies A...
(Date:12/1/2009)... Uninsured patients in California are unable to su...dical care at hospitals despite recent state legis...ording to a new study. , Posing as low-income un...ates from less than one-third of the hospitals the... much higher than those allowed under California l...
(Date:12/1/2009)...ethod improves diagnosis of benign versus cancerou...Dec. 1 (HealthDay News) -- When used with ultrasou...us and benign breast lesions, which reduces unnece...About 80 percent of breast lesions that are biopsi...n Cancer Society. , "There,s a lot of room to i...
(Date:12/1/2009)... Lumension announces gener... Security Suite to deliver end-to-end endpoint man...ent and single management console architecture. ,...cember 1, 2009 -- Lumension, a global leader in en... new Lumension® Endpoint Management and Secur...
Breaking Medicine News(10 mins):Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:The Forsyth Institute receives the William J. Gies Award for outstanding achievement 2Health News:Hospital price transparancy laws in California fall short, study finds 2Health News:Ultrasound With Elastography May Cut Down on Biopsies 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 3Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 4Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 5Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 6
...percent of the Market by 2013, According to a New ...., May 13 Decision Resources, one of the world,s ...armaceutical and healthcare issues, finds that the...will be fueled by an increased uptake of antimetab...
... JEFFERSONS RESTAURANT VIP PREMIERE GALA, What...nday, May 18, 2009, Where: 1033 Jefferson Stre...on Street is known for its legendary live concerts...tic location. In keeping with its pioneering legac...
...iver disease and characterized by excessive collag...evious work, p90RSK is observed significantly up-r...e I levels in rat liver fibrosis. But detail mecha...y addresses this question. The research team led ...
... B (NPR-B) gene was expressed in gastric smooth mu...on was increased in diabetic rats. These results s... signal is up-regulated and it may contribute to d...ed complication of long-standing diabetes. Symptom...
...CE) study estimates prevalence of 3 to 8 million w...NGTON, May 13 Three to eight million women in the.... This newly released prevalence number, presente... has IC and what it is results from an expansive a...
...oudly announce positive results for the CriticalPo...and Products 2nd annual national survey. , , ENGL...he positive customer satisfaction results for the ...harmacy Purchasing and Products in its 2nd annual...
Other Medicine News:Health News:India's Non-Small-Cell Lung Cancer Drug Market Will Almost Double by 2013 2Health News:Belmont University Graduate Launches Healthy Soul Food Restaurant on Nashville's Historic Jefferson Street 2Health News:NPs-NPR-B/pGC-cGMP signal pathway is involved in diabetic gastroparesis 2Health News:Prevalence of Interstitial Cystitis in U.S. Much Larger Than Previously Believed 2Health News:CriticalPoint(TM) Training Rated 'Excellent' in Customer Satisfaction 2Health News:CriticalPoint(TM) Training Rated 'Excellent' in Customer Satisfaction 3
(Date:12/1/2009)...wswire/ -- MedNet Solutions, a global life science...nical study management systems, today announced th...inical technology solution, has been certified by ... (CDISC) as complying with the Operational Data Mo...s MedNet,s commitment to streamlining the entire c...
(Date:12/1/2009)...Dec. 1 The educational r..... Improving Life," created by Lilly USA (NYSE: ...th.com/value_of_medicine.jsp . The booklet support...tter" and encourages an open dialogue with patient...utical industry practices. ,, "Today, Lilly an...
(Date:12/1/2009)...wswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Amex...censed to Chrono Nutraceuticals LLC exclusive righ... release dietary supplements using SCOLR,s proprie...n, SCOLR granted Chrono rights to manufacture and ...a nonexclusive basis. Chrono paid SCOLR $25,000 u...
Breaking Medicine Technology:MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification 2Lilly Releases Latest 'Value of Medicine' Resource Guide About Key Issues Facing the Pharmaceutical Industry 2Lilly Releases Latest 'Value of Medicine' Resource Guide About Key Issues Facing the Pharmaceutical Industry 3Lilly Releases Latest 'Value of Medicine' Resource Guide About Key Issues Facing the Pharmaceutical Industry 4SCOLR Pharma, Inc. Licenses Dietary Supplements 2SCOLR Pharma, Inc. Licenses Dietary Supplements 3Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31 2009 14556 1Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31 2009 14556 2Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31 2009 14556 3Infant sucking habits may affect how baby talks 10453 1Infant sucking habits may affect how baby talks 10453 2NHP Announces Third Quarter Earnings Release Date and Webcast Conference Call 59874 1NHP Announces Third Quarter Earnings Release Date and Webcast Conference Call 59874 2
...25 Data from a 52-week phase 3,study (LEADTM 3) o...-daily,human GLP-1 analog, were published online t...ide, when taken alone, produces statistically,sign...control in patients,with early type 2 diabetes, as...i-diabetic drug. Moreover, the treatment with lira...
.... 25 Snack-sized quantities of,walnuts slow cance...lot,study published in the current issue of the pe...cher W. Elaine Hardman, Ph.D., of Marshall,s Joan ...esigned to determine whether mice,that got part of...t cancer,growth than a group eating a diet more ty...
Other Medicine Technology:Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 2Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 3Eating Walnuts Slows Cancer Growth, Laboratory Study Finds 2
Acri.Sil-oI 1000
Ispan SF6 Intraocular Gases
Silikon 1000 Silicone Oil
Foreign body spud
Medicine Products: